Phase 4 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male and aged 12 years or older at the time of signing the consent form
- You have been diagnosed with severe congenital hemophilia A, meaning your body produces less than 1% of the normal level of clotting factor VIII, confirmed by a lab test or medical records
- You have a history of inhibitors (antibodies that block hemophilia treatment), shown by specific blood test results or past medical records showing an immune response to treatment (confirm with trial site)
- You are currently taking the full prescribed dose of emicizumab as a preventive treatment, regardless of whether you have inhibitors or not
- You have read, understood, and signed the consent form agreeing to follow the trial's requirements
Who may not be able to join:
- You have another condition that affects bleeding or blood clotting
- You have a history of antiphospholipid antibody syndrome (a disorder where the immune system mistakenly attacks certain proteins in the blood)
- You have had a blood clot in an artery or vein, an irregular heartbeat (atrial fibrillation), significant heart valve problems, a heart attack, chest pain (angina), a mini-stroke, or a stroke — though clots related to a medical line or port may not disqualify you (confirm with trial site)
- You have a significant liver disease
- You have previously taken part in a trial involving a drug called fitusiran
- You have previously taken part in a gene therapy trial
- Your antithrombin activity level (a protein involved in blood clotting) is below 60% on your screening blood test (confirm with trial site)
- You have a hereditary or acquired condition that increases your risk of blood clots
- You have a hepatitis C infection, unless your virus levels are undetectable and you do not have liver scarring (cirrhosis)
- You currently have an acute hepatitis A or hepatitis E infection
- You have an active hepatitis B infection
- You are HIV positive with a very low immune cell count (fewer than 200 CD4 cells per microlitre of blood)
- You have reduced kidney function
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Sciences & Operations, Sanofi
Phone: 800-633-1610
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with Adverse events (AEs) during the fitusiran treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.